COVID Vaccine Developer Announcements [selected]

Milestones :: Perspectives :: Research


COVID Vaccine Developer Announcements [selected]


Moderna Announces New Supply Agreement with the Philippines for 7 Million Additional Doses of COVID-19 Vaccine Moderna
March 22, 2021


EMA Approves New Storage Option for Pfizer-BioNTech Vaccine, Easing Distribution and Storage of Doses Across European Union
March 26, 2021
:: New stability data show vaccine can be stored at -25°C to -15°C for a total of two weeks and support decentralized distribution plans for vaccination at general practitioners’ offices
:: Label update offers greater flexibility for distributing, storing and administering the vaccine within the European Union

Pfizer Initiates Phase 1 Study of Novel Oral Antiviral Therapeutic Agent Against SARS-CoV-2
March 23, 2021
:: In-vitro studies conducted to date show that the clinical candidate PF-07321332 is a potent protease inhibitor with potent anti-viral activity against SARS-CoV-2
:: This is the first orally administered coronavirus-specific investigational protease inhibitor to be evaluated in clinical studies, and follows Pfizer’s intravenously administered investigational protease inhibitor, which is currently being evaluated in a Phase 1b multi-dose study in hospitalized clinical trial participants with COVID-19


Press Releases
AZD1222 US Phase III primary analysis confirms safety and efficacy
25 March 2021


Statement on COVID-19 vaccine supply at Anagni plant in Italy
24 March 2021


Update following statement by NIAID on AZD1222 US Phase III trial data
23 March 2021


AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis
22 March 2021